Opinion

Video

Bladder Cancer: Highlights from ESMO 2023 and Ongoing Developments

Author(s):

Axel Merseburger, MD, PhD,M. Carmen Mir, MD, PhD

The expert panel reviews highlights from ESMO 2023 and discusses ongoing developments in the treatment landscape for bladder cancer.

Related Videos
Suzanne B. Merrill, MD, FACS, answers a question during a Zoom video interview
Urinary bladder | Image Credit: © magicmine - stock.adobe.com
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
Betty Wang, MD, discusses studies from the 2025 EAU meeting
Joshua J. Meeks, MD, PhD, answers a question during a Zoom video interview
Human urinary bladder | Image Credit: © magicmine - stock.adobe.com
Related Content
Welcome to Fabulous Las Vegas Neon Sign | Image Credit: © somchaij - stock.adobe.com
April 21st 2025

AUA 2025: What to watch for in urologic oncology

Benjamin P. Saylor Hannah Clarke
We preview several noteworthy P2 presentations in the urologic oncology space.
Dr. Schwen on focal therapies for prostate cancer
January 11th 2024

Dr. Schwen on focal therapies for prostate cancer

Cleveland Clinic
Zeyad Schwen, MD, a urologic oncologist at Cleveland Clinic, discusses how patient factors and cancer characteristics are key to deciding between focal therapies and whole gland treatment for prostate cancer.
3d rendered illustration - bladder cancer | Image Credit: © Sebastian Kaulitzki - stock.adobe.com
April 17th 2025

NMIBC Clinical Forums highlight novel therapies and treatment strategies

Urology Times staff
Two recent Clinical Forum discussions sought to examine how emerging therapeutic options and evolving treatment standards in non–muscle invasive bladder cancer affect clinical practices and patient outcomes.
medical depiction of bladder cancer
May 31st 2023

Bladder Cancer Awareness Month: Dr. Kamat highlights the state of bladder cancer care

Urology Times staff
In this episode, Ashish M. Kamat, MD, MBBS, highlights the state of bladder cancer care in recognition of Bladder Cancer Awareness Month.
FDA approval sought for Anktiva in papillary NMIBC
April 15th 2025

FDA approval sought for Anktiva in papillary NMIBC

Hannah Clarke
The sBLA is supported by data from cohort B of the pivotal QUILT-3.032 trial.
Label change for testosterone: Implications for urologists, prescribers, and patients
April 9th 2025

Label change for testosterone: Implications for urologists, prescribers, and patients

Hannah Clarke
In February 2025, the FDA recommended a removal of the black box warning related to an increased risk of adverse cardiovascular outcomes for all testosterone products. This recommendation has important implications for urologists and the patients they treat.
© 2025 MJH Life Sciences

All rights reserved.